KR20050085170A - 당뇨병 치료에 유용한 아닐리노피라졸 유도체 - Google Patents

당뇨병 치료에 유용한 아닐리노피라졸 유도체 Download PDF

Info

Publication number
KR20050085170A
KR20050085170A KR1020057009560A KR20057009560A KR20050085170A KR 20050085170 A KR20050085170 A KR 20050085170A KR 1020057009560 A KR1020057009560 A KR 1020057009560A KR 20057009560 A KR20057009560 A KR 20057009560A KR 20050085170 A KR20050085170 A KR 20050085170A
Authority
KR
South Korea
Prior art keywords
optionally substituted
alkoxy
alkyl
group
halo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020057009560A
Other languages
English (en)
Korean (ko)
Inventor
요아킴 루돌프
루이스-데이빗 캔틴
스티븐 매그누슨
윌리암 불록
앤-메리 불리온
리빙 첸
치 유안 추앙
시드니 리양
디유티 마줌다르
허버트 오구투
앨런 올레이그
닝 퀴
필립 엘. 위킨스
Original Assignee
바이엘 파마슈티칼스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 파마슈티칼스 코포레이션 filed Critical 바이엘 파마슈티칼스 코포레이션
Publication of KR20050085170A publication Critical patent/KR20050085170A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020057009560A 2002-11-27 2003-11-25 당뇨병 치료에 유용한 아닐리노피라졸 유도체 Withdrawn KR20050085170A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42991702P 2002-11-27 2002-11-27
US60/429,917 2002-11-27
US49821403P 2003-08-27 2003-08-27
US60/498,214 2003-08-27

Publications (1)

Publication Number Publication Date
KR20050085170A true KR20050085170A (ko) 2005-08-29

Family

ID=32474531

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057009560A Withdrawn KR20050085170A (ko) 2002-11-27 2003-11-25 당뇨병 치료에 유용한 아닐리노피라졸 유도체

Country Status (16)

Country Link
US (2) US7265144B2 (cg-RX-API-DMAC7.html)
EP (1) EP1567517A1 (cg-RX-API-DMAC7.html)
JP (1) JP2006510728A (cg-RX-API-DMAC7.html)
KR (1) KR20050085170A (cg-RX-API-DMAC7.html)
AR (1) AR042067A1 (cg-RX-API-DMAC7.html)
AU (2) AU2003295890A1 (cg-RX-API-DMAC7.html)
BR (1) BR0316723A (cg-RX-API-DMAC7.html)
CA (1) CA2507186A1 (cg-RX-API-DMAC7.html)
HN (1) HN2003000379A (cg-RX-API-DMAC7.html)
MX (1) MXPA05004621A (cg-RX-API-DMAC7.html)
MY (1) MY141528A (cg-RX-API-DMAC7.html)
PE (1) PE20040907A1 (cg-RX-API-DMAC7.html)
PL (1) PL377164A1 (cg-RX-API-DMAC7.html)
TW (1) TW200418803A (cg-RX-API-DMAC7.html)
UY (1) UY28098A1 (cg-RX-API-DMAC7.html)
WO (2) WO2004050650A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2567352A1 (en) * 2004-05-20 2005-12-01 Bayer Pharmaceuticals Corporation 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
EP1860098B1 (en) 2005-03-16 2012-11-14 Toyama Chemical Co., Ltd. Novel anthranilic acid derivative or salt thereof
ES2400371T3 (es) * 2005-07-07 2013-04-09 Abbott Laboratories Promotores de la apoptosis
CA2620425A1 (en) * 2005-08-31 2007-03-08 Bayer Healthcare Llc Anilinopyrazole derivatives useful for the treatment of diabetes
WO2007129195A2 (en) * 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
ATE550326T1 (de) * 2006-07-31 2012-04-15 Cadila Healthcare Ltd Als modulatoren von hdl einsetzbare verbindungen
AU2007305016B2 (en) 2006-10-02 2011-11-03 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
CA2698928A1 (en) * 2007-09-28 2009-04-09 Absolute Science, Inc. Compounds and methods for treating zinc matrix metalloprotease dependent diseases
DE102008039083A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Aminopyrazole und ihre Verwendung
DE102008039082A1 (de) 2008-08-21 2010-02-25 Bayer Schering Pharma Aktiengesellschaft Azabicyclisch-substituierte 5-Aminopyrazole und ihre Verwendung
WO2010033360A1 (en) * 2008-09-19 2010-03-25 1/3 Absolute Science, Inc. Methods of treating a botulinum toxin related condition in a subject
MX2011002793A (es) 2008-09-25 2011-04-05 Hoffmann La Roche Derivados de 3-amino-indazol o de 3-amino-4,5,6,7-tetrahidro-indaz ol.
AR075713A1 (es) 2009-03-03 2011-04-20 Du Pont Pirazoles fungicidas
TWI504350B (zh) * 2010-09-01 2015-10-21 Du Pont 殺真菌吡唑及其混合物
TWI568721B (zh) 2012-02-01 2017-02-01 杜邦股份有限公司 殺真菌之吡唑混合物
US9630976B2 (en) 2012-07-03 2017-04-25 Ono Pharmaceutical Co., Ltd. Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes
CN103074693A (zh) * 2013-01-18 2013-05-01 桐昆集团股份有限公司 带双导丝辊的poy纺丝卷绕装置
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
EP3805213A3 (en) 2015-06-18 2021-06-09 Nippon Soda Co., Ltd. 1-(2-(ethylsulfonyl)-phenyl)-4-(phenyl)-1h-1,2,3-triazole and 4-(2-(ethylsulfonyl)-phenyl)-1-(phenyl)-1h-1,2,3-triazole and related compounds derivatives as pesticides
KR102420892B1 (ko) * 2017-05-26 2022-07-14 쟝쑤 애텀 바이오사이언스 앤드 파머수티컬 컴퍼니 리미티드 요산 배출을 촉진시키는 urat1 억제제
WO2020227368A1 (en) * 2019-05-08 2020-11-12 Trustees Of Boston University Hsp90 inhibitors and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL134200C (cg-RX-API-DMAC7.html) 1960-04-14
US3790576A (en) 1972-03-20 1974-02-05 Parke Davis & Co 9 substituted 4,9-dihydro-1,3,4,4-tetraalkyl-1h-pyrazolo(3,4-b)quinolines
HUT69739A (en) 1992-03-26 1995-09-28 Dowelanco Process for producing n-heterocyclic nitroanilines and fungicides containing the compounds
CA2203517A1 (en) 1994-11-10 1996-05-23 Alan M. Laibelman Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases
DE19532066A1 (de) 1995-08-31 1997-03-06 Bayer Ag Substituierte 5-Aminopyrazole
FR2763334A1 (fr) * 1997-05-13 1998-11-20 Lipha Derives anthraniliques
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
US5942520A (en) 1998-01-27 1999-08-24 Cell Pathways, Inc. Method for inhibiting neoplastic cells by exposure to substituted N-cycloalkylmethyl-1-H-pyrazolo (3,4-B) quinolone-4 amines
EP1597234B1 (en) * 2003-02-27 2008-10-08 Smithkline Beecham Corporation Novel compounds

Also Published As

Publication number Publication date
US7265144B2 (en) 2007-09-04
CA2507186A1 (en) 2004-06-17
HN2003000379A (es) 2005-12-20
AU2003297565A1 (en) 2004-06-23
UY28098A1 (es) 2004-06-30
AU2003295890A1 (en) 2004-06-23
US20040157904A1 (en) 2004-08-12
US20080064734A1 (en) 2008-03-13
TW200418803A (en) 2004-10-01
WO2004050651A1 (en) 2004-06-17
PE20040907A1 (es) 2005-01-27
EP1567517A1 (en) 2005-08-31
MY141528A (en) 2010-05-14
PL377164A1 (pl) 2006-01-23
WO2004050650A1 (en) 2004-06-17
BR0316723A (pt) 2005-10-18
AR042067A1 (es) 2005-06-08
JP2006510728A (ja) 2006-03-30
MXPA05004621A (es) 2005-06-08
HK1087103A1 (zh) 2006-10-06

Similar Documents

Publication Publication Date Title
US20080064734A1 (en) Anilinopyrazole derivatives useful for the treatment of diabetes
US20090209451A1 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
JP6948322B2 (ja) Apj受容体のapjアゴニストとしてのヘテロアリールヒドロキシピリミジノン
US20210002289A1 (en) Monofunctional intermediates for ligand-dependent target protein degradation
WO2020114482A1 (zh) 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
JP6177768B2 (ja) ベンズアミド誘導体
US11345669B2 (en) Urea derivatives and methods of use thereof
US7176314B2 (en) Inflammation modulators
KR102336371B1 (ko) 테트라졸론-치환된 디히드로피리디논 mgat2 억제제
KR102291444B1 (ko) 디히드로피리디논 mgat2 억제제
WO2021219078A1 (zh) 基于杂环和戊二酰亚胺骨架的化合物及其应用
CA2513631A1 (fr) Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
KR20130097776A (ko) 사이클로프로판 화합물
CN115380036A (zh) Sstr5拮抗剂
CN105308046A (zh) 激酶抑制剂
CN103974953A (zh) 激酶抑制剂
EP3759095A1 (en) Compounds and compositions for treating conditions associated with apj receptor activity
JP2009506127A (ja) 糖尿病の処置に有用なアニリノピラゾール誘導体
US10214530B2 (en) Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same
US20080009531A1 (en) 5-Anilino-4-Heteroarylpyrazole Derivatives Useful for the Treatment of Diabetes
ES2313985T3 (es) Imidazoles sutituidos como agonistas o antagonistas de histamina h1 y h3.
HK1087103B (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MXPA06008833A (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
KR20260054550A (ko) JAK1를 선택적으로 저해하는 신규한 테트라하이드로이소퀴놀린 또는 이소인돌린 치환 [1,2,4]트리아졸로[1,5-a]피리딘 유도체 및 이의 용도

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050526

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid